REG - Diaceutics PLC - Diaceutics PLC – Financial Calendar Update

DiaceuticsAnnouncement

19/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240119:nRSS1787Aa&default-theme=true

RNS Number : 1787A  Diaceutics PLC  19 January 2024

Diaceutics PLC - Financial Calendar Update

 

Belfast and London, 19 January 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to pharma and biotech companies, today
announces the following financial calendar events.

 

·    January 30, 2024 - Trading Update for the 12 months ended 31 December
2023

·    May 21, 2024 - Preliminary results for the full year ended 31
December 2023

·    June 24, 2024 - Annual General Meeting of shareholders

 

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBBGDBCGBDGSI